Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

Open access
Wen, P. Y., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., Drappatz, J., Groves, M. D., Santagata, S., Ligon, A. H., Yung, W. K. A., Wright, J. J., Dancey, J., Aldape, K. D., Prados, M. D., Ligon, K. L.·2014·Neuro-Oncology

Abstract

BACKGROUND: Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma patients. METHODS: We conducted a phase I/II study of the EGFR inhibitor erlotinib (150 mg/day) and the mTOR inhibitor temsirolimus. Patients initially received temsirolimus 50 mg weekly, and the dose adjusted based on toxicities. In the phase II component, the primary endpoint was 6-month progression-free survival (PFS6) among glioblastoma patients. RESULTS: Twenty-two patients enrolled in phase I, 47 in phase II. Twelve phase I patients treated at the maximum tolerated dosage were included in the phase II cohort for analysis. The maximum tolerated dosage was 15 mg temsirolimus weekly with erlotinib 150 mg daily. Dose-limiting toxicities were rash and mucositis. Among 42 evaluable glioblastoma patients, 12 (29%) achieved stable disease, but there were no responses, and PFS6 was 13%. Among 16 anaplastic glioma patients, 1 (6%) achieved complete response, 1 (6%) partial response, and 2 (12.5%) stable disease, with PFS6 of 8%. Tumor levels of both drugs were low, and posttreatment tissue in 3 patients showed no reduction in the mTOR target phosphorylated (phospho-)S6(S235/236) but possible compensatory increase in phospho-Akt(S473). Presence of EGFR variant III, phospho-EGFR, and EGFR amplification did not correlate with survival, but patients with elevated phospho-extracellular signal-regulated kinase or reduced phosphatase and tensin homolog protein expression had decreased progression-free survival at 4 months. CONCLUSION: Because of increased toxicity, the maximum tolerated dosage of temsirolimus in combination with erlotinib proved lower than expected. Insufficient tumor drug levels and redundant signaling pathways may partly explain the minimal antitumor activity noted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/not247

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 171

Metadata

Authors
Wen, P. Y., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., Drappatz, J., Groves, M. D., Santagata, S., Ligon, A. H., Yung, W. K. A., Wright, J. J., Dancey, J., Aldape, K. D., Prados, M. D., & Ligon, K. L.
Venue
Neuro-Oncology
Published
2014-01-26
Volume
16
Issue
4
Pages
567-578
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2168687763
Cited by
171
References
11
FWCI
8.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. https://app.cochat.ai/papers/10.1093/neuonc/not247
The paper
Wen, P. Y., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., Drappatz, J., Groves, M. D., Santagata, S., Ligon, A. H., Yung, W. K. A., Wright, J. J., Dancey, J., Aldape, K. D., Prados, M. D., & Ligon, K. L. (2014). Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. https://doi.org/10.1093/neuonc/not247

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.